Section 1: The Deal Beneath the Deal: Why Licensing Structure Reveals Strategic Intent A pharmaceutical patent licensing agreement is not […]

I. Executive Summary and Key Takeaways Patient advocacy groups (PAGs) have crossed a threshold. They are no longer peripheral voices

Executive Summary Chiral switching built billion-dollar franchises in the 1990s and early 2000s. The model was straightforward: isolate the active

I. Why Generic Drug Economics Punish Mediocrity The generic drug market runs on a brutal arithmetic. Generics account for 90%

KSM designation is not a paperwork exercise. It is one of the earliest and highest-leverage decisions in pharmaceutical development, with

1. The Economic Architecture of the Patent Bargain 1a. What the Patent System Actually Incentivizes The pharmaceutical patent system rests

A definitive reference covering stereochemical science, the 1992 FDA policy and its commercial aftershocks, chiral separation technology roadmaps, Forest Labs

How to read the FDA’s most underused signal, map the Hatch-Waxman timeline with precision, and turn patent intelligence into a

1. Why the PTAB Is the Single Most Important Variable in Pharmaceutical Patent Valuation Analysts who model pharmaceutical patent portfolios